Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family

Immunity

Volumn 44, Issue 5, 2016, Pages 955-972

  Schildberg, Frank A ^a   Klein, Sarah R ^a   Freeman, Gordon J ^a   Sharpe, Arlene H ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN 2; B7 CD28 LIGAND RECEPTOR; BUTYROPHILIN LIKE 2; CD276 ANTIGEN; CD28 ANTIGEN; CD8 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; HUMAN ENDOGENOUS RETROVIRUS H LONG TERMINAL REPEAT ASSOCIATING PROTEIN 2; IPILIMUMAB; LIGAND; MESSENGER RNA; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG; V DOMAIN IMMUNOGLOBULIN SUPPRESSOR OF T CELL ACTIVATION; V SET DOMAIN CONTAINING T CELL ACTIVATION INHIBITOR 1; B7 ANTIGEN; MONOCLONAL ANTIBODY;

AMINO ACID SEQUENCE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DNA POLYMORPHISM; GENE STRUCTURE; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STRUCTURE; REVIEW; T LYMPHOCYTE; ANIMAL; AUTOIMMUNE DISEASES; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LYMPHOCYTE ACTIVATION; METABOLISM; NEOPLASMS; PROCEDURES; SIGNAL TRANSDUCTION; TRANSPLANTATION; TRENDS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD28; AUTOIMMUNE DISEASES; B7 ANTIGENS; HUMANS; IMMUNE TOLERANCE; IMMUNOSUPPRESSION; IMMUNOTHERAPY; INFECTION; LYMPHOCYTE ACTIVATION; NEOPLASMS; RECEPTOR CROSS-TALK; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 84966738229     PISSN: 10747613     EISSN: 10974180     Source Type: Journal    
DOI: 10.1016/j.immuni.2016.05.002     Document Type: Review

References (208)

1. Abadi Y.M., Jeon H., Ohaegbulam K.C., Scandiuzzi L., Ghosh K., Hofmeyer K.A., Lee J.S., Ray A., Gravekamp C., Zang X. Host b7x promotes pulmonary metastasis of breast cancer. J. Immunol. 2013, 190:3806-3814.
2. Agata Y., Kawasaki A., Nishimura H., Ishida Y., Tsubata T., Yagita H., Honjo T. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int. Immunol. 1996, 8:765-772.
3. Alegre M.L., Noel P.J., Eisfelder B.J., Chuang E., Clark M.R., Reiner S.L., Thompson C.B. Regulation of surface and intracellular expression of CTLA4 on mouse T cells. J. Immunol. 1996, 157:4762-4770.
4. Aloia L., Parisi S., Fusco L., Pastore L., Russo T. Differentiation of embryonic stem cells 1 (Dies1) is a component of bone morphogenetic protein 4 (BMP4) signaling pathway required for proper differentiation of mouse embryonic stem cells. J. Biol. Chem. 2010, 285:7776-7783.
5. Anderson A., Joller N., Kuchroo V. Lag-3, Tim-3, and TIGIT co-inhibitory receptors with specialized functions in immune regulation. Immunity 2016, 44:989-1004. this issue.
6. Anjos S., Nguyen A., Ounissi-Benkalha H., Tessier M.C., Polychronakos C. A common autoimmunity predisposing signal peptide variant of the cytotoxic T-lymphocyte antigen 4 results in inefficient glycosylation of the susceptibility allele. J. Biol. Chem. 2002, 277:46478-46486.
7. Ansell S.M., Lesokhin A.M., Borrello I., Halwani A., Scott E.C., Gutierrez M., Schuster S.J., Millenson M.M., Cattry D., Freeman G.J., et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N. Engl. J. Med. 2015, 372:311-319.
8. Araki M., Chung D., Liu S., Rainbow D.B., Chamberlain G., Garner V., Hunter K.M., Vijayakrishnan L., Peterson L.B., Oukka M., et al. Genetic evidence that the differential expression of the ligand-independent isoform of CTLA-4 is the molecular basis of the Idd5.1 type 1 diabetes region in nonobese diabetic mice. J. Immunol. 2009, 183:5146-5157.
9. Arnett H.A., Escobar S.S., Gonzalez-Suarez E., Budelsky A.L., Steffen L.A., Boiani N., Zhang M., Siu G., Brewer A.W., Viney J.L. BTNL2, a butyrophilin/B7-like molecule, is a negative costimulatory molecule modulated in intestinal inflammation. J. Immunol. 2007, 178:1523-1533.
10. Attanasio J., Wherry E.J. Costimulatory and coinhibitory receptor pathways in infectious disease. Immunity 2016, 44:1052-1068. this issue.
11. Austin J.W., Lu P., Majumder P., Ahmed R., Boss J.M. STAT3, STAT4, NFATc1, and CTCF regulate PD-1 through multiple novel regulatory regions in murine T cells. J. Immunol. 2014, 192:4876-4886.
12. Bachmann M.F., Köhler G., Ecabert B., Mak T.W., Kopf M. Cutting edge: lymphoproliferative disease in the absence of CTLA-4 is not T cell autonomous. J. Immunol. 1999, 163:1128-1131.
13. Bally A.P., Lu P., Tang Y., Austin J.W., Scharer C.D., Ahmed R., Boss J.M. NF-κB regulates PD-1 expression in macrophages. J. Immunol. 2015, 194:4545-4554.
14. Bour-Jordan H., Grogan J.L., Tang Q., Auger J.A., Locksley R.M., Bluestone J.A. CTLA-4 regulates the requirement for cytokine-induced signals in T(H)2 lineage commitment. Nat. Immunol. 2003, 4:182-188.
15. Bretscher P., Cohn M. A theory of self-nonself discrimination. Science 1970, 169:1042-1049.
16. Brunet J.F., Denizot F., Luciani M.F., Roux-Dosseto M., Suzan M., Mattei M.G., Golstein P. A new member of the immunoglobulin superfamily--CTLA-4. Nature 1987, 328:267-270.
17. Butte M.J., Keir M.E., Phamduy T.B., Sharpe A.H., Freeman G.J. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 2007, 27:111-122.
18. Callahan M.K., Postow M.A., Wolchok J.D. Targeting T cell co-receptors for cancer therapy. Immunity 2016, 44:1069-1078. this issue.
19. Ceeraz S., Nowak E.C., Noelle R.J. B7 family checkpoint regulators in immune regulation and disease. Trends Immunol. 2013, 34:556-563.
20. Chang W.S., Kim J.Y., Kim Y.J., Kim Y.S., Lee J.M., Azuma M., Yagita H., Kang C.Y. Cutting edge: Programmed death-1/programmed death ligand 1 interaction regulates the induction and maintenance of invariant NKT cell anergy. J. Immunol. 2008, 181:6707-6710.
21. Chang C.H., Curtis J.D., Maggi L.B., Faubert B., Villarino A.V., O'Sullivan D., Huang S.C., van der Windt G.J., Blagih J., Qiu J., et al. Posttranscriptional control of T cell effector function by aerobic glycolysis. Cell 2013, 153:1239-1251.
22. Chang C.H., Qiu J., O'Sullivan D., Buck M.D., Noguchi T., Curtis J.D., Chen Q., Gindin M., Gubin M.M., van der Windt G.J., et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell 2015, 162:1229-1241.
23. Chapoval A.I., Ni J., Lau J.S., Wilcox R.A., Flies D.B., Liu D., Dong H., Sica G.L., Zhu G., Tamada K., Chen L. B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production. Nat. Immunol. 2001, 2:269-274.
24. Chattopadhyay G., Shevach E.M. Antigen-specific induced T regulatory cells impair dendritic cell function via an IL-10/MARCH1-dependent mechanism. J. Immunol. 2013, 191:5875-5884.
25. Chemnitz J.M., Parry R.V., Nichols K.E., June C.H., Riley J.L. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J. Immunol. 2004, 173:945-954.
26. Chen X., Zhang G., Li Y., Feng X., Wan F., Zhang L., Wang J., Zhang X. Circulating B7-H3(CD276) elevations in cerebrospinal fluid and plasma of children with bacterial meningitis. J. Mol. Neurosci. 2009, 37:86-94.
27. Chen L., Gibbons D.L., Goswami S., Cortez M.A., Ahn Y.H., Byers L.A., Zhang X., Yi X., Dwyer D., Lin W., et al. Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat. Commun. 2014, 5:5241.
28. Cheng L., Jiang J., Gao R., Wei S., Nan F., Li S., Kong B. B7-H4 expression promotes tumorigenesis in ovarian cancer. Int. J. Gynecol. Cancer 2009, 19:1481-1486.
29. Cho H.Y., Lee S.W., Seo S.K., Choi I.W., Choi I., Lee S.W. Interferon-sensitive response element (ISRE) is mainly responsible for IFN-alpha-induced upregulation of programmed death-1 (PD-1) in macrophages. Biochim. Biophys. Acta 2008, 1779:811-819.
30. Choi I.H., Zhu G., Sica G.L., Strome S.E., Cheville J.C., Lau J.S., Zhu Y., Flies D.B., Tamada K., Chen L. Genomic organization and expression analysis of B7-H4, an immune inhibitory molecule of the B7 family. J. Immunol. 2003, 171:4650-4654.
31. Chuang E., Fisher T.S., Morgan R.W., Robbins M.D., Duerr J.M., Vander Heiden M.G., Gardner J.P., Hambor J.E., Neveu M.J., Thompson C.B. The CD28 and CTLA-4 receptors associate with the serine/threonine phosphatase PP2A. Immunity 2000, 13:313-322.
32. Collins A.V., Brodie D.W., Gilbert R.J., Iaboni A., Manso-Sancho R., Walse B., Stuart D.I., van der Merwe P.A., Davis S.J. The interaction properties of costimulatory molecules revisited. Immunity 2002, 17:201-210.
33. Collins M., Ling V., Carreno B.M. The B7 family of immune-regulatory ligands. Genome Biol. 2005, 6:223.
34. Corse E., Allison J.P. Cutting edge: CTLA-4 on effector T cells inhibits in trans. J. Immunol. 2012, 189:1123-1127.
35. Cunningham A.J., Lafferty K.J. A simple conservative explanation of the H-2 restriction of interactions between lymphocytes. Scand. J. Immunol. 1977, 6:1-6.
36. Dariavach P., Mattéi M.G., Golstein P., Lefranc M.P. Human Ig superfamily CTLA-4 gene: chromosomal localization and identity of protein sequence between murine and human CTLA-4 cytoplasmic domains. Eur. J. Immunol. 1988, 18:1901-1905.
37. de Jong V.M., Zaldumbide A., van der Slik A.R., Persengiev S.P., Roep B.O., Koeleman B.P. Post-transcriptional control of candidate risk genes for type 1 diabetes by rare genetic variants. Genes Immun. 2013, 14:58-61.
38. Deichmann K., Heinzmann A., Brüggenolte E., Forster J., Kuehr J. An Mse I RFLP in the human CTLA4 promotor. Biochem. Biophys. Res. Commun. 1996, 225:817-818.
39. Dong H., Strome S.E., Salomao D.R., Tamura H., Hirano F., Flies D.B., Roche P.C., Lu J., Zhu G., Tamada K., et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 2002, 8:793-800.
40. Donner H., Rau H., Walfish P.G., Braun J., Siegmund T., Finke R., Herwig J., Usadel K.H., Badenhoop K. CTLA4 alanine-17 confers genetic susceptibility to Graves' disease and to type 1 diabetes mellitus. J. Clin. Endocrinol. Metab. 1997, 82:143-146.
41. Eppihimer M.J., Gunn J., Freeman G.J., Greenfield E.A., Chernova T., Erickson J., Leonard J.P. Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells. Microcirculation 2002, 9:133-145.
42. Esensten J.H., Helou Y.A., Chopra G., Weiss A., Bluestone J.A. CD28 costimulation: from mechanism to therapy. Immunity 2016, 44:973-988. this issue.
43. Esposito L., Hunter K.M., Clark J., Rainbow D.B., Stevens H., Denesha J., Duley S., Dawson S., Coleman G., Nutland S., et al. Investigation of soluble and transmembrane CTLA-4 isoforms in serum and microvesicles. J. Immunol. 2014, 193:889-900.
44. Fallarino F., Grohmann U., Hwang K.W., Orabona C., Vacca C., Bianchi R., Belladonna M.L., Fioretti M.C., Alegre M.L., Puccetti P. Modulation of tryptophan catabolism by regulatory T cells. Nat. Immunol. 2003, 4:1206-1212.
45. Fife B.T., Pauken K.E., Eagar T.N., Obu T., Wu J., Tang Q., Azuma M., Krummel M.F., Bluestone J.A. Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat. Immunol. 2009, 10:1185-1192.
46. Finn P.W., He H., Wang Y., Wang Z., Guan G., Listman J., Perkins D.L. Synergistic induction of CTLA-4 expression by costimulation with TCR plus CD28 signals mediated by increased transcription and messenger ribonucleic acid stability. J. Immunol. 1997, 158:4074-4081.
47. Flies D.B., Wang S., Xu H., Chen L. Cutting edge: A monoclonal antibody specific for the programmed death-1 homolog prevents graft-versus-host disease in mouse models. J. Immunol. 2011, 187:1537-1541.
48. + T cell-mediated immunity. J. Clin. Invest. 2014, 124:1966-1975.
49. Ford M.L. T cell cosignaling molecules in transplantation. Immunity 2016, 44:1020-1033. this issue.
50. Forni D., Cagliani R., Pozzoli U., Colleoni M., Riva S., Biasin M., Filippi G., De Gioia L., Gnudi F., Comi G.P., et al. A 175 million year history of T cell regulatory molecules reveals widespread selection, with adaptive evolution of disease alleles. Immunity 2013, 38:1129-1141.
51. Francisco L.M., Salinas V.H., Brown K.E., Vanguri V.K., Freeman G.J., Kuchroo V.K., Sharpe A.H. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J. Exp. Med. 2009, 206:3015-3029.
52. Freeman G.J., Lombard D.B., Gimmi C.D., Brod S.A., Lee K., Laning J.C., Hafler D.A., Dorf M.E., Gray G.S., Reiser H., et al. CTLA-4 and CD28 mRNA are coexpressed in most T cells after activation. Expression of CTLA-4 and CD28 mRNA does not correlate with the pattern of lymphokine production. J. Immunol. 1992, 149:3795-3801.
53. Frigola X., Inman B.A., Lohse C.M., Krco C.J., Cheville J.C., Thompson R.H., Leibovich B., Blute M.L., Dong H., Kwon E.D. Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma. Clin. Cancer Res. 2011, 17:1915-1923.
54. Gerold K.D., Zheng P., Rainbow D.B., Zernecke A., Wicker L.S., Kissler S. The soluble CTLA-4 splice variant protects from type 1 diabetes and potentiates regulatory T-cell function. Diabetes 2011, 60:1955-1963.
55. Gibson H.M., Hedgcock C.J., Aufiero B.M., Wilson A.J., Hafner M.S., Tsokos G.C., Wong H.K. Induction of the CTLA-4 gene in human lymphocytes is dependent on NFAT binding the proximal promoter. J. Immunol. 2007, 179:3831-3840.
56. Gong A.Y., Zhou R., Hu G., Li X., Splinter P.L., O'Hara S.P., LaRusso N.F., Soukup G.A., Dong H., Chen X.M. MicroRNA-513 regulates B7-H1 translation and is involved in IFN-gamma-induced B7-H1 expression in cholangiocytes. J. Immunol. 2009, 182:1325-1333.
57. Grohmann U., Orabona C., Fallarino F., Vacca C., Calcinaro F., Falorni A., Candeloro P., Belladonna M.L., Bianchi R., Fioretti M.C., Puccetti P. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat. Immunol. 2002, 3:1097-1101.
58. Hamanishi J., Mandai M., Iwasaki M., Okazaki T., Tanaka Y., Yamaguchi K., Higuchi T., Yagi H., Takakura K., Minato N., et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc. Natl. Acad. Sci. USA 2007, 104:3360-3365.
59. Han Y., Chen Z., Yang Y., Jiang Z., Gu Y., Liu Y., Lin C., Pan Z., Yu Y., Jiang M., et al. Human CD14+ CTLA-4+ regulatory dendritic cells suppress T-cell response by cytotoxic T-lymphocyte antigen-4-dependent IL-10 and indoleamine-2,3-dioxygenase production in hepatocellular carcinoma. Hepatology 2014, 59:567-579.
60. Harper K., Balzano C., Rouvier E., Mattéi M.G., Luciani M.F., Golstein P. CTLA-4 and CD28 activated lymphocyte molecules are closely related in both mouse and human as to sequence, message expression, gene structure, and chromosomal location. J. Immunol. 1991, 147:1037-1044.
61. Hashiguchi M., Kobori H., Ritprajak P., Kamimura Y., Kozono H., Azuma M. Triggering receptor expressed on myeloid cell-like transcript 2 (TLT-2) is a counter-receptor for B7-H3 and enhances T cell responses. Proc. Natl. Acad. Sci. USA 2008, 105:10495-10500.
62. He X.H., Xu L.H., Liu Y. Identification of a novel splice variant of human PD-L1 mRNA encoding an isoform-lacking Igv-like domain. Acta Pharmacol. Sin. 2005, 26:462-468.
63. Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., Gonzalez R., Robert C., Schadendorf D., Hassel J.C., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010, 363:711-723.
64. Iida T., Ohno H., Nakaseko C., Sakuma M., Takeda-Ezaki M., Arase H., Kominami E., Fujisawa T., Saito T. Regulation of cell surface expression of CTLA-4 by secretion of CTLA-4-containing lysosomes upon activation of CD4+ T cells. J. Immunol. 2000, 165:5062-5068.
65. Ise W., Kohyama M., Nutsch K.M., Lee H.M., Suri A., Unanue E.R., Murphy T.L., Murphy K.M. CTLA-4 suppresses the pathogenicity of self antigen-specific T cells by cell-intrinsic and cell-extrinsic mechanisms. Nat. Immunol. 2010, 11:129-135.
66. Ishida Y., Agata Y., Shibahara K., Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992, 11:3887-3895.
67. Janakiram M., Chinai J.M., Fineberg S., Fiser A., Montagna C., Medavarapu R., Castano E., Jeon H., Ohaegbulam K.C., Zhao R., et al. Expression, clinical significance, and receptor identification of the newest B7 family member HHLA2 protein. Clin. Cancer Res. 2015, 21:2359-2366.
68. Jones J.C., Freeman G.J. Costimulatory genes: hotspots of conflict between host defense and autoimmunity. Immunity 2013, 38:1083-1085.
69. Kaku H., Rothstein T.L. Octamer binding protein 2 (Oct2) regulates PD-L2 gene expression in B-1 cells through lineage-specific activity of a unique, intronic promoter. Genes Immun. 2010, 11:55-66.
70. Kao C., Oestreich K.J., Paley M.A., Crawford A., Angelosanto J.M., Ali M.A., Intlekofer A.M., Boss J.M., Reiner S.L., Weinmann A.S., Wherry E.J. Transcription factor T-bet represses expression of the inhibitory receptor PD-1 and sustains virus-specific CD8+ T cell responses during chronic infection. Nat. Immunol. 2011, 12:663-671.
71. Kaufman K.A., Bowen J.A., Tsai A.F., Bluestone J.A., Hunt J.S., Ober C. The CTLA-4 gene is expressed in placental fibroblasts. Mol. Hum. Reprod. 1999, 5:84-87.
72. Kong K.F., Fu G., Zhang Y., Yokosuka T., Casas J., Canonigo-Balancio A.J., Becart S., Kim G., Yates J.R., Kronenberg M., et al. Protein kinase C-η controls CTLA-4-mediated regulatory T cell function. Nat. Immunol. 2014, 15:465-472.
73. Kowalczyk A., D'Souza C.A., Zhang L. Cell-extrinsic CTLA4-mediated regulation of dendritic cell maturation depends on STAT3. Eur. J. Immunol. 2014, 44:1143-1155.
74. Krambeck A.E., Thompson R.H., Dong H., Lohse C.M., Park E.S., Kuntz S.M., Leibovich B.C., Blute M.L., Cheville J.C., Kwon E.D. B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc. Natl. Acad. Sci. USA 2006, 103:10391-10396.
75. Kristiansen O.P., Larsen Z.M., Pociot F. CTLA-4 in autoimmune diseases--a general susceptibility gene to autoimmunity?. Genes Immun. 2000, 1:170-184.
76. Kroner A., Mehling M., Hemmer B., Rieckmann P., Toyka K.V., Mäurer M., Wiendl H. A PD-1 polymorphism is associated with disease progression in multiple sclerosis. Ann. Neurol. 2005, 58:50-57.
77. Kryczek I., Wei S., Zou L., Zhu G., Mottram P., Xu H., Chen L., Zou W. Cutting edge: induction of B7-H4 on APCs through IL-10: novel suppressive mode for regulatory T cells. J. Immunol. 2006, 177:40-44.
78. Kryczek I., Zou L., Rodriguez P., Zhu G., Wei S., Mottram P., Brumlik M., Cheng P., Curiel T., Myers L., et al. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J. Exp. Med. 2006, 203:871-881.
79. Kuehn H.S., Ouyang W., Lo B., Deenick E.K., Niemela J.E., Avery D.T., Schickel J.N., Tran D.Q., Stoddard J., Zhang Y., et al. Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4. Science 2014, 345:1623-1627.
80. Lafferty K.J., Cunningham A.J. A new analysis of allogeneic interactions. Aust. J. Exp. Biol. Med. Sci. 1975, 53:27-42.
81. Laurent S., Carrega P., Saverino D., Piccioli P., Camoriano M., Morabito A., Dozin B., Fontana V., Simone R., Mortara L., et al. CTLA-4 is expressed by human monocyte-derived dendritic cells and regulates their functions. Hum. Immunol. 2010, 71:934-941.
82. Leitner J., Klauser C., Pickl W.F., Stöckl J., Majdic O., Bardet A.F., Kreil D.P., Dong C., Yamazaki T., Zlabinger G., et al. B7-H3 is a potent inhibitor of human T-cell activation: No evidence for B7-H3 and TREML2 interaction. Eur. J. Immunol. 2009, 39:1754-1764.
83. Lindsten T., Lee K.P., Harris E.S., Petryniak B., Craighead N., Reynolds P.J., Lombard D.B., Freeman G.J., Nadler L.M., Gray G.S., et al. Characterization of CTLA-4 structure and expression on human T cells. J. Immunol. 1993, 151:3489-3499.
84. Lines J.L., Pantazi E., Mak J., Sempere L.F., Wang L., O'Connell S., Ceeraz S., Suriawinata A.A., Yan S., Ernstoff M.S., Noelle R. VISTA is an immune checkpoint molecule for human T cells. Cancer Res. 2014, 74:1924-1932.
85. Ling V., Munroe R.C., Murphy E.A., Gray G.S. Embryonic stem cells and embryoid bodies express lymphocyte costimulatory molecules. Exp. Cell Res. 1998, 241:55-65.
86. Linsley P.S., Brady W., Urnes M., Grosmaire L.S., Damle N.K., Ledbetter J.A. CTLA-4 is a second receptor for the B cell activation antigen B7. J. Exp. Med. 1991, 174:561-569.
87. Linsley P.S., Greene J.L., Tan P., Bradshaw J., Ledbetter J.A., Anasetti C., Damle N.K. Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes. J. Exp. Med. 1992, 176:1595-1604.
88. Linsley P.S., Nadler S.G., Bajorath J., Peach R., Leung H.T., Rogers J., Bradshaw J., Stebbins M., Leytze G., Brady W., et al. Binding stoichiometry of the cytotoxic T lymphocyte-associated molecule-4 (CTLA-4). A disulfide-linked homodimer binds two CD86 molecules. J. Biol. Chem. 1995, 270:15417-15424.
89. Linsley P.S., Bradshaw J., Greene J., Peach R., Bennett K.L., Mittler R.S. Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement. Immunity 1996, 4:535-543.
90. Liu Y., Yu Y., Yang S., Zeng B., Zhang Z., Jiao G., Zhang Y., Cai L., Yang R. Regulation of arginase I activity and expression by both PD-1 and CTLA-4 on the myeloid-derived suppressor cells. Cancer Immunol. Immunother. 2009, 58:687-697.
91. Liu S.M., Sutherland A.P., Zhang Z., Rainbow D.B., Quintana F.J., Paterson A.M., Sharpe A.H., Oukka M., Wicker L.S., Kuchroo V.K. Overexpression of the Ctla-4 isoform lacking exons 2 and 3 causes autoimmunity. J. Immunol. 2012, 188:155-162.
92. Liu Y., Carlsson R., Comabella M., Wang J., Kosicki M., Carrion B., Hasan M., Wu X., Montalban X., Dziegiel M.H., et al. FoxA1 directs the lineage and immunosuppressive properties of a novel regulatory T cell population in EAE and MS. Nat. Med. 2014, 20:272-282.
93. Liu J., Yuan Y., Chen W., Putra J., Suriawinata A.A., Schenk A.D., Miller H.E., Guleria I., Barth R.J., Huang Y.H., Wang L. Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses. Proc. Natl. Acad. Sci. USA 2015, 112:6682-6687.
94. Lo B., Zhang K., Lu W., Zheng L., Zhang Q., Kanellopoulou C., Zhang Y., Liu Z., Fritz J.M., Marsh R., et al. AUTOIMMUNE DISEASE. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy. Science 2015, 349:436-440.
95. Loke P., Allison J.P. PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. Proc. Natl. Acad. Sci. USA 2003, 100:5336-5341.
96. Loos M., Hedderich D.M., Friess H., Kleeff J. B7-h3 and its role in antitumor immunity. Clin. Dev. Immunol. 2010, 2010:683875.
97. Lu P., Youngblood B.A., Austin J.W., Mohammed A.U., Butler R., Ahmed R., Boss J.M. Blimp-1 represses CD8 T cell expression of PD-1 using a feed-forward transcriptional circuit during acute viral infection. J. Exp. Med. 2014, 211:515-527.
98. Luo L., Chapoval A.I., Flies D.B., Zhu G., Hirano F., Wang S., Lau J.S., Dong H., Tamada K., Flies A.S., et al. B7-H3 enhances tumor immunity in vivo by costimulating rapid clonal expansion of antigen-specific CD8+ cytolytic T cells. J. Immunol. 2004, 173:5445-5450.
99. Mager D.L., Hunter D.G., Schertzer M., Freeman J.D. Endogenous retroviruses provide the primary polyadenylation signal for two new human genes (HHLA2 and HHLA3). Genomics 1999, 59:255-263.
100. Magistrelli G., Jeannin P., Herbault N., Benoit De Coignac A., Gauchat J.F., Bonnefoy J.Y., Delneste Y. A soluble form of CTLA-4 generated by alternative splicing is expressed by nonstimulated human T cells. Eur. J. Immunol. 1999, 29:3596-3602.
101. Malquori L., Carsetti L., Ruberti G. The 3' UTR of the human CTLA4 mRNA can regulate mRNA stability and translational efficiency. Biochim. Biophys. Acta 2008, 1779:60-65.
102. Mathieu M., Cotta-Grand N., Daudelin J.F., Thébault P., Labrecque N. Notch signaling regulates PD-1 expression during CD8(+) T-cell activation. Immunol. Cell Biol. 2013, 91:82-88.
103. Mead K.I., Zheng Y., Manzotti C.N., Perry L.C., Liu M.K., Burke F., Powner D.J., Wakelam M.J., Sansom D.M. Exocytosis of CTLA-4 is dependent on phospholipase D and ADP ribosylation factor-1 and stimulated during activation of regulatory T cells. J. Immunol. 2005, 174:4803-4811.
104. Metzler W.J., Bajorath J., Fenderson W., Shaw S.Y., Constantine K.L., Naemura J., Leytze G., Peach R.J., Lavoie T.B., Mueller L., Linsley P.S. Solution structure of human CTLA-4 and delineation of a CD80/CD86 binding site conserved in CD28. Nat. Struct. Biol. 1997, 4:527-531.
105. Michalek R.D., Gerriets V.A., Jacobs S.R., Macintyre A.N., MacIver N.J., Mason E.F., Sullivan S.A., Nichols A.G., Rathmell J.C. Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets. J. Immunol. 2011, 186:3299-3303.
106. Miller R.E., Fayen J.D., Mohammad S.F., Stein K., Kadereit S., Woods K.D., Sramkoski R.M., Jacobberger J.W., Templeton D., Shurin S.B., Laughlin M.J. Reduced CTLA-4 protein and messenger RNA expression in umbilical cord blood T lymphocytes. Exp. Hematol. 2002, 30:738-744.
107. Mueller S.N., Vanguri V.K., Ha S.J., West E.E., Keir M.E., Glickman J.N., Sharpe A.H., Ahmed R. PD-L1 has distinct functions in hematopoietic and nonhematopoietic cells in regulating T cell responses during chronic infection in mice. J. Clin. Invest. 2010, 120:2508-2515.
108. Munn D.H., Shafizadeh E., Attwood J.T., Bondarev I., Pashine A., Mellor A.L. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J. Exp. Med. 1999, 189:1363-1372.
109. Nguyen T., Liu X.K., Zhang Y., Dong C. BTNL2, a butyrophilin-like molecule that functions to inhibit T cell activation. J. Immunol. 2006, 176:7354-7360.
110. Nielsen C., Ohm-Laursen L., Barington T., Husby S., Lillevang S.T. Alternative splice variants of the human PD-1 gene. Cell. Immunol. 2005, 235:109-116.
111. Nishimura H., Agata Y., Kawasaki A., Sato M., Imamura S., Minato N., Yagita H., Nakano T., Honjo T. Developmentally regulated expression of the PD-1 protein on the surface of double-negative (CD4-CD8-) thymocytes. Int. Immunol. 1996, 8:773-780.
112. Nisticò L., Buzzetti R., Pritchard L.E., Van der Auwera B., Giovannini C., Bosi E., Larrad M.T., Rios M.S., Chow C.C., Cockram C.S., et al. The CTLA-4 gene region of chromosome 2q33 is linked to, and associated with, type 1 diabetes. Belgian Diabetes Registry. Hum. Mol. Genet. 1996, 5:1075-1080.
113. Nomi T., Sho M., Akahori T., Hamada K., Kubo A., Kanehiro H., Nakamura S., Enomoto K., Yagita H., Azuma M., Nakajima Y. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin. Cancer Res. 2007, 13:2151-2157.
114. Nurieva R., Thomas S., Nguyen T., Martin-Orozco N., Wang Y., Kaja M.K., Yu X.Z., Dong C. T-cell tolerance or function is determined by combinatorial costimulatory signals. EMBO J. 2006, 25:2623-2633.
115. Oaks M.K., Hallett K.M., Penwell R.T., Stauber E.C., Warren S.J., Tector A.J. A native soluble form of CTLA-4. Cell. Immunol. 2000, 201:144-153.
116. Oestreich K.J., Yoon H., Ahmed R., Boss J.M. NFATc1 regulates PD-1 expression upon T cell activation. J. Immunol. 2008, 181:4832-4839.
117. Ohigashi Y., Sho M., Yamada Y., Tsurui Y., Hamada K., Ikeda N., Mizuno T., Yoriki R., Kashizuka H., Yane K., et al. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin. Cancer Res. 2005, 11:2947-2953.
118. Okazaki T., Maeda A., Nishimura H., Kurosaki T., Honjo T. PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc. Natl. Acad. Sci. USA 2001, 98:13866-13871.
119. Ostrov D.A., Shi W., Schwartz J.C., Almo S.C., Nathenson S.G. Structure of murine CTLA-4 and its role in modulating T cell responsiveness. Science 2000, 290:816-819.
120. Parry R.V., Chemnitz J.M., Frauwirth K.A., Lanfranco A.R., Braunstein I., Kobayashi S.V., Linsley P.S., Thompson C.B., Riley J.L. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol. Cell. Biol. 2005, 25:9543-9553.
121. Paterson A.M., Lovitch S.B., Sage P.T., Juneja V.R., Lee Y., Trombley J.D., Arancibia-Cárcamo C.V., Sobel R.A., Rudensky A.Y., Kuchroo V.K., et al. Deletion of CTLA-4 on regulatory T cells during adulthood leads to resistance to autoimmunity. J. Exp. Med. 2015, 212:1603-1621.
122. Patsoukis N., Brown J., Petkova V., Liu F., Li L., Boussiotis V.A. Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation. Sci. Signal. 2012, 5:ra46.
123. Patsoukis N., Li L., Sari D., Petkova V., Boussiotis V.A. PD-1 increases PTEN phosphatase activity while decreasing PTEN protein stability by inhibiting casein kinase 2. Mol. Cell. Biol. 2013, 33:3091-3098.
124. Patsoukis N., Bardhan K., Chatterjee P., Sari D., Liu B., Bell L.N., Karoly E.D., Freeman G.J., Petkova V., Seth P., et al. PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. Nat. Commun. 2015, 6:6692.
125. Pérez-García A., Osca G., Bosch-Vizcaya A., Kelleher N., Santos N.Y., Rodríguez R., González Y., Roncero J.M., Coll R., Serrando M., et al. Kinetics of the CTLA-4 isoforms expression after T-lymphocyte activation and role of the promoter polymorphisms on CTLA-4 gene transcription. Hum. Immunol. 2013, 74:1219-1224.
126. Petrovas C., Casazza J.P., Brenchley J.M., Price D.A., Gostick E., Adams W.C., Precopio M.L., Schacker T., Roederer M., Douek D.C., Koup R.A. PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection. J. Exp. Med. 2006, 203:2281-2292.
127. Pioli C., Gatta L., Ubaldi V., Doria G. Inhibition of IgG1 and IgE production by stimulation of the B cell CTLA-4 receptor. J. Immunol. 2000, 165:5530-5536.
128. Pistillo M.P., Tazzari P.L., Palmisano G.L., Pierri I., Bolognesi A., Ferlito F., Capanni P., Polito L., Ratta M., Pileri S., et al. CTLA-4 is not restricted to the lymphoid cell lineage and can function as a target molecule for apoptosis induction of leukemic cells. Blood 2003, 101:202-209.
129. Polanczyk M.J., Hopke C., Vandenbark A.A., Offner H. Estrogen-mediated immunomodulation involves reduced activation of effector T cells, potentiation of Treg cells, and enhanced expression of the PD-1 costimulatory pathway. J. Neurosci. Res. 2006, 84:370-378.
130. Prasad D.V., Nguyen T., Li Z., Yang Y., Duong J., Wang Y., Dong C. Murine B7-H3 is a negative regulator of T cells. J. Immunol. 2004, 173:2500-2506.
131. Prokunina L., Castillejo-López C., Oberg F., Gunnarsson I., Berg L., Magnusson V., Brookes A.J., Tentler D., Kristjansdóttir H., Gröndal G., et al. A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat. Genet. 2002, 32:666-669.
132. Qureshi O.S., Zheng Y., Nakamura K., Attridge K., Manzotti C., Schmidt E.M., Baker J., Jeffery L.E., Kaur S., Briggs Z., et al. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science 2011, 332:600-603.
133. Qureshi O.S., Kaur S., Hou T.Z., Jeffery L.E., Poulter N.S., Briggs Z., Kenefeck R., Willox A.K., Royle S.J., Rappoport J.Z., Sansom D.M. Constitutive clathrin-mediated endocytosis of CTLA-4 persists during T cell activation. J. Biol. Chem. 2012, 287:9429-9440.
134. Robert C., Thomas L., Bondarenko I., O'Day S., Weber J., Garbe C., Lebbe C., Baurain J.F., Testori A., Grob J.J., et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 2011, 364:2517-2526.
135. Sage P.T., Paterson A.M., Lovitch S.B., Sharpe A.H. The coinhibitory receptor CTLA-4 controls B cell responses by modulating T follicular helper, T follicular regulatory, and T regulatory cells. Immunity 2014, 41:1026-1039.
136. Sakr M.A., Takino T., Domoto T., Nakano H., Wong R.W., Sasaki M., Nakanuma Y., Sato H. GI24 enhances tumor invasiveness by regulating cell surface membrane-type 1 matrix metalloproteinase. Cancer Sci. 2010, 101:2368-2374.
137. Sakuishi K., Ngiow S.F., Sullivan J.M., Teng M.W., Kuchroo V.K., Smyth M.J., Anderson A.C. TIM3(+)FOXP3(+) regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer. OncoImmunology 2013, 2:e23849.
138. Salceda S., Tang T., Kmet M., Munteanu A., Ghosh M., Macina R., Liu W., Pilkington G., Papkoff J. The immunomodulatory protein B7-H4 is overexpressed in breast and ovarian cancers and promotes epithelial cell transformation. Exp. Cell Res. 2005, 306:128-141.
139. Scalapino K.J., Daikh D.I. CTLA-4: a key regulatory point in the control of autoimmune disease. Immunol. Rev. 2008, 223:143-155.
140. Schneider H., Martin M., Agarraberes F.A., Yin L., Rapoport I., Kirchhausen T., Rudd C.E. Cytolytic T lymphocyte-associated antigen-4 and the TCR zeta/CD3 complex, but not CD28, interact with clathrin adaptor complexes AP-1 and AP-2. J. Immunol. 1999, 163:1868-1879.
141. Schneider H., Smith X., Liu H., Bismuth G., Rudd C.E. CTLA-4 disrupts ZAP70 microcluster formation with reduced T cell/APC dwell times and calcium mobilization. Eur. J. Immunol. 2008, 38:40-47.
142. Sekulic A., Liang W.S., Tembe W., Izatt T., Kruglyak S., Kiefer J.A., Cuyugan L., Zismann V., Legendre C., Pittelkow M.R., et al. Personalized treatment of Sézary syndrome by targeting a novel CTLA4:CD28 fusion. Mol. Genet. Genomic Med. 2015, 3:130-136.
143. Selby M.J., Engelhardt J.J., Quigley M., Henning K.A., Chen T., Srinivasan M., Korman A.J. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol. Res. 2013, 1:32-42.
144. Sheppard K.A., Fitz L.J., Lee J.M., Benander C., George J.A., Wooters J., Qiu Y., Jussif J.M., Carter L.L., Wood C.R., Chaudhary D. PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta. FEBS Lett. 2004, 574:37-41.
145. Shinohara T., Taniwaki M., Ishida Y., Kawaichi M., Honjo T. Structure and chromosomal localization of the human PD-1 gene (PDCD1). Genomics 1994, 23:704-706.
146. Sica G.L., Choi I.H., Zhu G., Tamada K., Wang S.D., Tamura H., Chapoval A.I., Flies D.B., Bajorath J., Chen L. B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity 2003, 18:849-861.
147. Sonkoly E., Janson P., Majuri M.L., Savinko T., Fyhrquist N., Eidsmo L., Xu N., Meisgen F., Wei T., Bradley M., et al. MiR-155 is overexpressed in patients with atopic dermatitis and modulates T-cell proliferative responses by targeting cytotoxic T lymphocyte-associated antigen 4. J. Allergy Clin. Immunol. 2010, 126. 581-9.e1, 20.
148. Staron M.M., Gray S.M., Marshall H.D., Parish I.A., Chen J.H., Perry C.J., Cui G., Li M.O., Kaech S.M. The transcription factor FoxO1 sustains expression of the inhibitory receptor PD-1 and survival of antiviral CD8(+) T cells during chronic infection. Immunity 2014, 41:802-814.
149. Steinberger P., Majdic O., Derdak S.V., Pfistershammer K., Kirchberger S., Klauser C., Zlabinger G., Pickl W.F., Stöckl J., Knapp W. Molecular characterization of human 4Ig-B7-H3, a member of the B7 family with four Ig-like domains. J. Immunol. 2004, 172:2352-2359.
150. Stojanovic A., Fiegler N., Brunner-Weinzierl M., Cerwenka A. CTLA-4 is expressed by activated mouse NK cells and inhibits NK cell IFN-γ production in response to mature dendritic cells. J. Immunol. 2014, 192:4184-4191.
151. Suh W.K., Gajewska B.U., Okada H., Gronski M.A., Bertram E.M., Dawicki W., Duncan G.S., Bukczynski J., Plyte S., Elia A., et al. The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses. Nat. Immunol. 2003, 4:899-906.
152. Suh W.K., Wang S., Duncan G.S., Miyazaki Y., Cates E., Walker T., Gajewska B.U., Deenick E., Dawicki W., Okada H., et al. Generation and characterization of B7-H4/B7S1/B7x-deficient mice. Mol. Cell. Biol. 2006, 26:6403-6411.
153. Sun M., Richards S., Prasad D.V., Mai X.M., Rudensky A., Dong C. Characterization of mouse and human B7-H3 genes. J. Immunol. 2002, 168:6294-6297.
154. Sun X., Vale M., Leung E., Kanwar J.R., Gupta R., Krissansen G.W. Mouse B7-H3 induces antitumor immunity. Gene Ther. 2003, 10:1728-1734.
155. Sun J., Fu F., Gu W., Yan R., Zhang G., Shen Z., Zhou Y., Wang H., Shen B., Zhang X. Origination of new immunological functions in the costimulatory molecule B7-H3: the role of exon duplication in evolution of the immune system. PLoS ONE 2011, 6:e24751.
156. Swanson R.M., Gavin M.A., Escobar S.S., Rottman J.B., Lipsky B.P., Dube S., Li L., Bigler J., Wolfson M., Arnett H.A., Viney J.L. Butyrophilin-like 2 modulates B7 costimulation to induce Foxp3 expression and regulatory T cell development in mature T cells. J. Immunol. 2013, 190:2027-2035.
157. Tai X., Van Laethem F., Sharpe A.H., Singer A. Induction of autoimmune disease in CTLA-4-/- mice depends on a specific CD28 motif that is required for in vivo costimulation. Proc. Natl. Acad. Sci. USA 2007, 104:13756-13761.
158. Takahashi T., Tagami T., Yamazaki S., Uede T., Shimizu J., Sakaguchi N., Mak T.W., Sakaguchi S. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J. Exp. Med. 2000, 192:303-310.
159. Terawaki S., Chikuma S., Shibayama S., Hayashi T., Yoshida T., Okazaki T., Honjo T. IFN-α directly promotes programmed cell death-1 transcription and limits the duration of T cell-mediated immunity. J. Immunol. 2011, 186:2772-2779.
160. Tivol E.A., Borriello F., Schweitzer A.N., Lynch W.P., Bluestone J.A., Sharpe A.H. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995, 3:541-547.
161. Ueda H., Howson J.M., Esposito L., Heward J., Snook H., Chamberlain G., Rainbow D.B., Hunter K.M., Smith A.N., Di Genova G., et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 2003, 423:506-511.
162. Ungewickell A., Bhaduri A., Rios E., Reuter J., Lee C.S., Mah A., Zehnder A., Ohgami R., Kulkarni S., Armstrong R., et al. Genomic analysis of mycosis fungoides and Sézary syndrome identifies recurrent alterations in TNFR2. Nat. Genet. 2015, 47:1056-1060.
163. Valentonyte R., Hampe J., Huse K., Rosenstiel P., Albrecht M., Stenzel A., Nagy M., Gaede K.I., Franke A., Haesler R., et al. Sarcoidosis is associated with a truncating splice site mutation in BTNL2. Nat. Genet. 2005, 37:357-364.
164. Valk E., Leung R., Kang H., Kaneko K., Rudd C.E., Schneider H. T cell receptor-interacting molecule acts as a chaperone to modulate surface expression of the CTLA-4 coreceptor. Immunity 2006, 25:807-821.
165. Vijayakrishnan L., Slavik J.M., Illés Z., Greenwald R.J., Rainbow D., Greve B., Peterson L.B., Hafler D.A., Freeman G.J., Sharpe A.H., et al. An autoimmune disease-associated CTLA-4 splice variant lacking the B7 binding domain signals negatively in T cells. Immunity 2004, 20:563-575.
166. Walunas T.L., Lenschow D.J., Bakker C.Y., Linsley P.S., Freeman G.J., Green J.M., Thompson C.B., Bluestone J.A. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994, 1:405-413.
167. Walunas T.L., Bakker C.Y., Bluestone J.A. CTLA-4 ligation blocks CD28-dependent T cell activation. J. Exp. Med. 1996, 183:2541-2550.
168. Wan B., Nie H., Liu A., Feng G., He D., Xu R., Zhang Q., Dong C., Zhang J.Z. Aberrant regulation of synovial T cell activation by soluble costimulatory molecules in rheumatoid arthritis. J. Immunol. 2006, 177:8844-8850.
169. Wang X.B., Giscombe R., Yan Z., Heiden T., Xu D., Lefvert A.K. Expression of CTLA-4 by human monocytes. Scand. J. Immunol. 2002, 55:53-60.
170. Wang X.B., Zhao X., Giscombe R., Lefvert A.K. A CTLA-4 gene polymorphism at position -318 in the promoter region affects the expression of protein. Genes Immun. 2002, 3:233-234.
171. Wang L., Fraser C.C., Kikly K., Wells A.D., Han R., Coyle A.J., Chen L., Hancock W.W. B7-H3 promotes acute and chronic allograft rejection. Eur. J. Immunol. 2005, 35:428-438.
172. Wang L., Rubinstein R., Lines J.L., Wasiuk A., Ahonen C., Guo Y., Lu L.F., Gondek D., Wang Y., Fava R.A., et al. VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses. J. Exp. Med. 2011, 208:577-592.
173. Wang C.J., Kenefeck R., Wardzinski L., Attridge K., Manzotti C., Schmidt E.M., Qureshi O.S., Sansom D.M., Walker L.S. Cutting edge: cell-extrinsic immune regulation by CTLA-4 expressed on conventional T cells. J. Immunol. 2012, 189:1118-1122.
174. Wang H., Wang K., Zhong X., Dai Y., Wu A., Li Y., Hu X. Plasma sCD28, sCTLA-4 levels in neuromyelitis optica and multiple sclerosis during relapse. J. Neuroimmunol. 2012, 243:52-55.
175. Wang L., Le Mercier I., Putra J., Chen W., Liu J., Schenk A.D., Nowak E.C., Suriawinata A.A., Li J., Noelle R.J. Disruption of the immune-checkpoint VISTA gene imparts a proinflammatory phenotype with predisposition to the development of autoimmunity. Proc. Natl. Acad. Sci. USA 2014, 111:14846-14851.
176. Ward-Kavanagh L.K., Lin W.W., Šedý J.R., Ware C.F. The TNF receptor superfamily in co-stimulating and co-inhibitory responses. Immunity 2016, 44:1005-1019. this issue.
177. Waterhouse P., Penninger J.M., Timms E., Wakeham A., Shahinian A., Lee K.P., Thompson C.B., Griesser H., Mak T.W. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 1995, 270:985-988.
178. Wei F., Zhong S., Ma Z., Kong H., Medvec A., Ahmed R., Freeman G.J., Krogsgaard M., Riley J.L. Strength of PD-1 signaling differentially affects T-cell effector functions. Proc. Natl. Acad. Sci. USA 2013, 110:E2480-E2489.
179. Wells A.D. Cyclin-dependent kinases: molecular switches controlling anergy and potential therapeutic targets for tolerance. Semin. Immunol. 2007, 19:173-179.
180. Wicker L.S., Chamberlain G., Hunter K., Rainbow D., Howlett S., Tiffen P., Clark J., Gonzalez-Munoz A., Cumiskey A.M., Rosa R.L., et al. Fine mapping, gene content, comparative sequencing, and expression analyses support Ctla4 and Nramp1 as candidates for Idd5.1 and Idd5.2 in the nonobese diabetic mouse. J. Immunol. 2004, 173:164-173.
181. Wing K., Onishi Y., Prieto-Martin P., Yamaguchi T., Miyara M., Fehervari Z., Nomura T., Sakaguchi S. CTLA-4 control over Foxp3+ regulatory T cell function. Science 2008, 322:271-275.
182. Wing J.B., Ise W., Kurosaki T., Sakaguchi S. Regulatory T cells control antigen-specific expansion of Tfh cell number and humoral immune responses via the coreceptor CTLA-4. Immunity 2014, 41:1013-1025.
183. Wu Y., Borde M., Heissmeyer V., Feuerer M., Lapan A.D., Stroud J.C., Bates D.L., Guo L., Han A., Ziegler S.F., et al. FOXP3 controls regulatory T cell function through cooperation with NFAT. Cell 2006, 126:375-387.
184. Xiao Y., Freeman G.J. A new B7:CD28 family checkpoint target for cancer immunotherapy: HHLA2. Clin. Cancer Res. 2015, 21:2201-2203.
185. Xiao G., Deng A., Liu H., Ge G., Liu X. Activator protein 1 suppresses antitumor T-cell function via the induction of programmed death 1. Proc. Natl. Acad. Sci. USA 2012, 109:15419-15424.
186. Xiao Y., Yu S., Zhu B., Bedoret D., Bu X., Francisco L.M., Hua P., Duke-Cohan J.S., Umetsu D.T., Sharpe A.H., et al. RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance. J. Exp. Med. 2014, 211:943-959.
187. Xu H., Cheung I.Y., Guo H.F., Cheung N.K. MicroRNA miR-29 modulates expression of immunoinhibitory molecule B7-H3: potential implications for immune based therapy of human solid tumors. Cancer Res. 2009, 69:6275-6281.
188. Yamazaki T., Akiba H., Iwai H., Matsuda H., Aoki M., Tanno Y., Shin T., Tsuchiya H., Pardoll D.M., Okumura K., et al. Expression of programmed death 1 ligands by murine T cells and APC. J. Immunol. 2002, 169:5538-5545.
189. Yao Y., Wang X., Jin K., Zhu J., Wang Y., Xiong S., Mao Y., Zhou L. B7-H4 is preferentially expressed in non-dividing brain tumor cells and in a subset of brain tumor stem-like cells. J. Neurooncol. 2008, 89:121-129.
190. Ying H., Yang L., Qiao G., Li Z., Zhang L., Yin F., Xie D., Zhang J. Cutting edge: CTLA-4--B7 interaction suppresses Th17 cell differentiation. J. Immunol. 2010, 185:1375-1378.
191. Yokosuka T., Takamatsu M., Kobayashi-Imanishi W., Hashimoto-Tane A., Azuma M., Saito T. Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. J. Exp. Med. 2012, 209:1201-1217.
192. Yoo H.Y., Kim P., Kim W.S., Lee S.H., Kim S., Kang S.Y., Jang H.Y., Lee J.E., Kim J., Kim S.J., et al. Frequent CTLA4-CD28 gene fusion in diverse types of T cell lymphoma. Haematologica. 2016, Published online January 27, 2016. haematol.2015.139253.
193. Youngblood B., Oestreich K.J., Ha S.J., Duraiswamy J., Akondy R.S., West E.E., Wei Z., Lu P., Austin J.W., Riley J.L., et al. Chronic virus infection enforces demethylation of the locus that encodes PD-1 in antigen-specific CD8(+) T cells. Immunity 2011, 35:400-412.
194. Zhang Q., Vignali D.A.A. Co-stimulatory and co-inhibitory pathways in autoimmunity. Immunity 2016, 44:1034-1051. this issue.
195. Zhang X., Schwartz J.C., Guo X., Bhatia S., Cao E., Lorenz M., Cammer M., Chen L., Zhang Z.Y., Edidin M.A., et al. Structural and functional analysis of the costimulatory receptor programmed death-1. Immunity 2004, 20:337-347.
196. Zhang G., Hou J., Shi J., Yu G., Lu B., Zhang X. Soluble CD276 (B7-H3) is released from monocytes, dendritic cells and activated T cells and is detectable in normal human serum. Immunology 2008, 123:538-546.
197. Zhang G., Liu Z., Duan S., Han Q., Li Z., Lv Y., Chen J., Lou S., Li N. Association of polymorphisms of programmed cell death-1 gene with chronic hepatitis B virus infection. Hum. Immunol. 2010, 71:1209-1213.
198. Zhang G., Wang J., Kelly J., Gu G., Hou J., Zhou Y., Redmond H.P., Wang J.H., Zhang X. B7-H3 augments the inflammatory response and is associated with human sepsis. J. Immunol. 2010, 185:3677-3684.
199. Zhang L., Wu H., Lu D., Li G., Sun C., Song H., Li J., Zhai T., Huang L., Hou C., et al. The costimulatory molecule B7-H4 promote tumor progression and cell proliferation through translocating into nucleus. Oncogene 2013, 32:5347-5358.
200. Zhang G., Li N., Li Z., Zhu Q., Li F., Yang C., Han Q., Lv Y., Zhou Z., Liu Z. microRNA-4717 differentially interacts with its polymorphic target in the PD1 3' untranslated region: A mechanism for regulating PD-1 expression and function in HBV-associated liver diseases. Oncotarget 2015, 6:18933-18944.
201. Zhao R., Chinai J.M., Buhl S., Scandiuzzi L., Ray A., Jeon H., Ohaegbulam K.C., Ghosh K., Zhao A., Scharff M.D., Zang X. HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell function. Proc. Natl. Acad. Sci. USA 2013, 110:9879-9884.
202. Zheng Y., Josefowicz S.Z., Kas A., Chu T.T., Gavin M.A., Rudensky A.Y. Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells. Nature 2007, 445:936-940.
203. Zheng L., Li D., Wang F., Wu H., Li X., Fu J., Chen X., Wang L., Liu Y., Wang S. Association between hepatitis B viral burden in chronic infection and a functional single nucleotide polymorphism of the PDCD1 gene. J. Clin. Immunol. 2010, 30:855-860.
204. Zhong X., Bai C., Gao W., Strom T.B., Rothstein T.L. Suppression of expression and function of negative immune regulator PD-1 by certain pattern recognition and cytokine receptor signals associated with immune system danger. Int. Immunol. 2004, 16:1181-1188.
205. + T cell immunity by a novel PD1 isoform-based fusion DNA vaccine. Mol. Ther. 2013, 21:1445-1455.
206. Zhou J., Cheung A.K., Tan Z., Wang H., Yu W., Du Y., Kang Y., Lu X., Liu L., Yuen K.Y., Chen Z. PD1-based DNA vaccine amplifies HIV-1 GAG-specific CD8+ T cells in mice. J. Clin. Invest. 2013, 123:2629-2642.
207. Zhu G., Augustine M.M., Azuma T., Luo L., Yao S., Anand S., Rietz A.C., Huang J., Xu H., Flies A.S., et al. B7-H4-deficient mice display augmented neutrophil-mediated innate immunity. Blood 2009, 113:1759-1767.
208. Zhu Y., Yao S., Iliopoulou B.P., Han X., Augustine M.M., Xu H., Phennicie R.T., Flies S.J., Broadwater M., Ruff W., et al. B7-H5 costimulates human T cells via CD28H. Nat. Commun. 2013, 4:2043.